Interferons and interferon-related pathways in heart disease
Interferons (IFNs) and IFN-related pathways play key roles in the defence against microbial infection. However, these processes may also be activated during the pathogenesis of non-infectious diseases, where they may contribute to organ injury, or function in a compensatory manner. In this review, w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1357343/full |
| _version_ | 1797214695335133184 |
|---|---|
| author | Duc Tin Tran Sri Nagarjun Batchu Andrew Advani |
| author_facet | Duc Tin Tran Sri Nagarjun Batchu Andrew Advani |
| author_sort | Duc Tin Tran |
| collection | DOAJ |
| description | Interferons (IFNs) and IFN-related pathways play key roles in the defence against microbial infection. However, these processes may also be activated during the pathogenesis of non-infectious diseases, where they may contribute to organ injury, or function in a compensatory manner. In this review, we explore the roles of IFNs and IFN-related pathways in heart disease. We consider the cardiac effects of type I IFNs and IFN-stimulated genes (ISGs); the emerging role of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway; the seemingly paradoxical effects of the type II IFN, IFN-γ; and the varied actions of the interferon regulatory factor (IRF) family of transcription factors. Recombinant IFNs and small molecule inhibitors of mediators of IFN receptor signaling are already employed in the clinic for the treatment of some autoimmune diseases, infections, and cancers. There has also been renewed interest in IFNs and IFN-related pathways because of their involvement in SARS-CoV-2 infection, and because of the relatively recent emergence of cGAS-STING as a pattern recognition receptor-activated pathway. Whether these advances will ultimately result in improvements in the care of those experiencing heart disease remains to be determined. |
| first_indexed | 2024-04-24T11:18:15Z |
| format | Article |
| id | doaj.art-8e495ca44f914cf7a0adb6ced8192321 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-24T11:18:15Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-8e495ca44f914cf7a0adb6ced81923212024-04-11T05:11:57ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2024-04-011110.3389/fcvm.2024.13573431357343Interferons and interferon-related pathways in heart diseaseDuc Tin TranSri Nagarjun BatchuAndrew AdvaniInterferons (IFNs) and IFN-related pathways play key roles in the defence against microbial infection. However, these processes may also be activated during the pathogenesis of non-infectious diseases, where they may contribute to organ injury, or function in a compensatory manner. In this review, we explore the roles of IFNs and IFN-related pathways in heart disease. We consider the cardiac effects of type I IFNs and IFN-stimulated genes (ISGs); the emerging role of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway; the seemingly paradoxical effects of the type II IFN, IFN-γ; and the varied actions of the interferon regulatory factor (IRF) family of transcription factors. Recombinant IFNs and small molecule inhibitors of mediators of IFN receptor signaling are already employed in the clinic for the treatment of some autoimmune diseases, infections, and cancers. There has also been renewed interest in IFNs and IFN-related pathways because of their involvement in SARS-CoV-2 infection, and because of the relatively recent emergence of cGAS-STING as a pattern recognition receptor-activated pathway. Whether these advances will ultimately result in improvements in the care of those experiencing heart disease remains to be determined.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1357343/fullinterferoninterferon-stimulated geneheart failuremyocardial infarctioncGAS-STINGinterferon regulatory factor |
| spellingShingle | Duc Tin Tran Sri Nagarjun Batchu Andrew Advani Interferons and interferon-related pathways in heart disease Frontiers in Cardiovascular Medicine interferon interferon-stimulated gene heart failure myocardial infarction cGAS-STING interferon regulatory factor |
| title | Interferons and interferon-related pathways in heart disease |
| title_full | Interferons and interferon-related pathways in heart disease |
| title_fullStr | Interferons and interferon-related pathways in heart disease |
| title_full_unstemmed | Interferons and interferon-related pathways in heart disease |
| title_short | Interferons and interferon-related pathways in heart disease |
| title_sort | interferons and interferon related pathways in heart disease |
| topic | interferon interferon-stimulated gene heart failure myocardial infarction cGAS-STING interferon regulatory factor |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1357343/full |
| work_keys_str_mv | AT ductintran interferonsandinterferonrelatedpathwaysinheartdisease AT srinagarjunbatchu interferonsandinterferonrelatedpathwaysinheartdisease AT andrewadvani interferonsandinterferonrelatedpathwaysinheartdisease |